… In fact activating mutations in PI3K gene or PTEN loss of function were shown to … the response
of KRAS mutant cancer cells to MEK inhibitors [84]. The concomitant inhibition of the ERK …

… It is known that MEK inhibitors, such as … KRAS mutant tumor rely on MAPK signaling
pathway [7]. However, drug resistance to MEK inhibitors has been reported in cancer with KRAS …

… To more directly interrogate the effects of SHP2 inhibition on other KRAS mutants, we
used RAS-less mouse embryonic fibroblasts (MEF; ref. 19). As in MIAPaCa-2 cells, …

Our unbiased preclinical studies have identified vincristine as an effective combination
partner for the MEK inhibitor trametinib and provide a novel therapeutic option to be studied in …

… To address an unmet clinical need to compare the efficacy of MEK inhibitors against different
KRAS mutations, we used two KRAS-mutant GEMMs, KRAS G12C and Kras G12D , to test …

… in combination with MEK inhibitor trametinib suppressed growth or induced apoptosis in the
KRAS-mutant lung adenocarcinoma cell line H441 and EGFR-mutant lung adenocarcinoma …

… or ERK (proteins in the RAS pathway) can reverse PARP inhibitor resistance in KRAS
mutant tumors. MEK and PARP inhibitors are clinically approved drugs that provide a readily …

… Based on the fact that KRAS mutant lung and colon cancer cell lines are unresponsive to
MEK inhibitors, and with the emergence of the proof that dual EGFR and ERBB2 inhibitor …

… of KRAS mutant NSCLC cells with the MEK inhibitor … Given this relative resistance, we
explored whether MEK inhibitor-… cell line A549 with the MEK inhibitor trametinib, especially in …

… , we substituted a KRAS-G12C inhibitor, ARS-1620 (20), for the MEK inhibitor. We found …
(NSCLC) cell lines harboring KRAS mutations show an increased sensitivity to MEK and IGF1R …